Secondary analysis of a randomised placebo-controlled trial: in autoimmune rheumatic disease, seroconversion after two recombinant zoster vaccine doses was similar with or without IV cyclophosphamide (91.9% vs 91.5%), but lower than healthy controls (99.4%).
Secondary analysisn = 369
Aikawa et al. Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide